Communiqués Gilead Sciences, Inc. Sao Paulo

Actions

GILD34

BRGILDBDR000

Produits pharmaceutiques

Marché Fermé - Sao Paulo Autres places de cotation 18:00:32 22/07/2026			Varia. 5j.	Varia. 1 janv.
333,62 ^BRL	+0,99%		-1,14%	-3,01%

22/07	Ebola : quels vaccins et traitements sont en cours de développement contre la souche Bundibugyo	RE
21/07	L'action Gilead Sciences recule après une dégradation de Leerink Partners	MT

Communiqués

21/07	Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026	BU
21/07	Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure	BU
02/07	Gilead Sciences : Supports the PARTNERS Trial to Advance Research on Potential Treatments for Ebola Virus Disease	PU
24/06	U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer	BU
23/06	European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors	BU
16/06	U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention	AQ
15/06	U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention	BU
12/06	Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief	BU
11/06	National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership	BU
09/06	UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir	AQ
05/06	Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa	BU
02/06	Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)	BU
27/05	Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)	BU
22/05	FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)	BU
22/05	Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors	BU
21/05	New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology	BU
21/05	Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio	BU
21/05	Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease	BU
15/05	Gilead Prices $3 Billion of Senior Unsecured Notes	BU
13/05	Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026	BU
08/05	Gilead Sciences : First Quarter 2026 Resource Book	PU
08/05	Gilead Sciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
08/05	Gilead Sciences : First Quarter 2026 Prepared Remarks	PU
08/05	Gilead Sciences : First Quarter 2026 Summary of Remarks	PU
07/05	Gilead Sciences : First Quarter 2026 Supplementary Information	PU